First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Early data are coming with the KRAS G12D degrader ARV-806.
A first-in-human trial of PRT12396 starts next month.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
